Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for alendronate
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on alendronate or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on alendronate and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. 9682041 1998 08 04 1998 08 04 2013 11 21 0028-4793 339 5 1998 Jul 30 The New England journal of medicine N. Engl. J. Med. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. 292-9 Osteoporosis is a common complication of long-term glucocorticoid therapy (...) for which there is no well-proved preventive or restorative treatment. We carried out two 48-week, randomized, placebo-controlled studies of two doses of alendronate in 477 men and women, 17 to 83 years of age, who were receiving glucocorticoid therapy. The primary end point was the difference in the mean percent change in lumbar-spine bone density from base line to week 48 between the groups. Secondary outcomes included changes in bone density of the hip, biochemical markers of bone turnover
Prevention of nonvertebral fractures by alendronate: a meta-analysis Prevention of nonvertebral fractures by alendronate: a meta-analysis Prevention of nonvertebral fractures by alendronate: a meta-analysis Karpf D B, Shapiro D R, Seeman E, Ensrud K E, Johnston C C, Adami S, Harris S T, Santora A C, Hirsch L J, Oppenheimer L, Thompson D Authors' objectives To evaluate the effect of treatment with alendronate sodium, an aminobisphosphonate, on the incidence of nonvertebral fractures in post (...) -menopausal women with osteoporosis. Searching Studies were sought from published data and data on file at Merck Research Laboratories. No search details were provided. Study selection Study designs of evaluations included in the review The studies evaluated were all randomised, prospective double-blind placebo controlled trials of at least two years duration that evaluated the efficacy of treatment with daily oral alendronate. Specific interventions included in the review Daily treatment with various
[Use of alendronate in osteoporosis: is it cost-effective?] Bruk av alendronat ved osteoporose: er det kostnadseffektivt? [Use of alendronate in osteoporosis: is it cost-effective?] Bruk av alendronat ved osteoporose: er det kostnadseffektivt? [Use of alendronate in osteoporosis: is it cost-effective?] Kristiansen I S, Falch J A, Andersen L, Aursnes I Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains (...) a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of alendronate in the treatment of osteoporosis. Type of intervention Treatment, primary prevention and secondary prevention. Economic study type Cost-effectiveness analysis and cost-utility analysis. Study population Women with a bone mass density (BMD) less than 2.5 standard deviations below maximum BMD (the WHO
Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. 8950879 1997 01 02 1997 01 02 2016 11 24 0140-6736 348 9041 1996 Dec 07 Lancet (London, England) Lancet Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. 1535-41 Previous studies have shown that alendronate can increase bone mineral density (BMD (...) ) and prevent radiographically defined (morphometric) vertebral fractures. The Fracture Intervention Trial aimed to investigate the effect of alendronate on the risk of morphometric as well as clinically evident fractures in postmenopausal women with low bone mass. Women aged 55-81 with low femoral-neck BMD were enrolled in two study groups based on presence or absence of an existing vertebral fracture. Results for women with at least one vertebral fracture at baseline are reported here. 2027 women
Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. 7477143 1995 12 01 1995 12 01 2013 11 21 0028-4793 333 22 1995 Nov 30 The New England journal of medicine N. Engl. J. Med. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. 1437-43 Postmenopausal (...) osteoporosis is a serious health problem, and additional treatments are needed. We studied the effects of oral alendronate, an aminobisphosphonate, on bone mineral density and the incidence of fractures and height loss in 994 women with postmenopausal osteoporosis. The women were treated with placebo or alendronate (5 or 10 mg daily for three years, or 20 mg for two years followed by 5 mg for one year); all the women received 500 mg of calcium daily. Bone mineral density was measured by dual-energy x-ray